Grandfield & Dodd LLC Sells 7,500 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Grandfield & Dodd LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 38,370 shares of the medical equipment provider’s stock after selling 7,500 shares during the period. Grandfield & Dodd LLC’s holdings in Zimmer Biomet were worth $3,500,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Accent Capital Management LLC bought a new stake in Zimmer Biomet during the first quarter valued at $35,000. Cullen Frost Bankers Inc. boosted its position in shares of Zimmer Biomet by 1,452.4% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 305 shares in the last quarter. Hilltop National Bank bought a new stake in Zimmer Biomet in the second quarter worth approximately $42,000. True Wealth Design LLC increased its holdings in Zimmer Biomet by 875.0% in the second quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 420 shares in the last quarter. Finally, Zions Bancorporation National Association UT acquired a new position in Zimmer Biomet in the first quarter valued at approximately $48,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $90.36 on Friday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The stock has a market cap of $17.91 billion, a PE ratio of 21.98, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The stock’s fifty day simple moving average is $98.88 and its two-hundred day simple moving average is $97.19. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.72.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is currently 23.76%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZBH shares. Barclays dropped their target price on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 5th. Rothschild & Co Redburn began coverage on Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price for the company. BTIG Research dropped their price target on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Finally, Canaccord Genuity Group decreased their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $109.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.